| abstract |
Use of a compound of general formula (I) or salt thereof wherein R and R4 are independently selected from hydrogen, halogen and C¿1-6? alkyl or haloalkyl, C2-6 alkenyl or haloalkenyl, C1-6 alkoxy, phenoxy, C1-6 alkylthio, phenylthio, primary and secondary amino or hydroxy groups and R?3¿ is hydrogen, hydroxy, a C¿1-6? alkyl or haloalkyl, C2-6 alkenyl or haloalkenyl or C1-6 alkoxy or haloalkoxy group is provided for the manufacture of a medicament for the treatment of neoplasms, particularly solid cancerous tumours characterised in that R?1¿ is selected from a C¿1-6? alkyl or haloalkyl group, -CO2R?5¿ where R5 is hydrogen or a C¿1-6? alkyl or haloalkyl group, or a group -CH2-X where X is selected from groups of formula -S-R?6, -O-R6¿, and (a) where R6 is a hydrogen or a leaving group, the acid HR6 of which has a pKa of 10 or less and R?7 and R8¿ are the same or different and are selected from C¿1-6? alkyl or haloalkyl or together with the interjacent nitrogen form a heterocyclic ring of 5 to 7 atoms optionally substituted by C1-4 alkyl or haloalkyl and R?2¿ is selected from hydrogen, C¿1-4? alkyl and haloalkyl or groups-(CH2)nCHR?9R10¿ of more than four carbon atoms where n is an integer of 0 to 2 and R?9 and R10¿ are independently selected from a C¿1-4? alkyl or haloalkyl group, or R?9 and R10¿ together with the interjacent carbon atom form a C¿3-7? cycloalkyl or cycloalkenyl ring optionally substituted with one or more C1-4 alkyl or haloalkyl, or C2-4 alkenyl or haloalkenyl groups. |